Your essential monthly update on health tech's progress

Welcome to your monthly snapshot of the facts, figures, opinions, trends and challenges shaping the development of health tech.

Our monthly tracker report aims to provide a concise update for busy health tech professionals on the many factors influencing your work.

Here you will find a breakdown of deals, developments and opportunities from the last 30 days; and insight and opinion from leading thinkers in the field.

We hope you find something useful and/or inspiring below - and welcome any feedback about what else you'd like to see included. And don't forget you can find daily updates on the health tech sector on our website.

Many thanks for your interest in Health Tech World

Andrew Mernin
Editorial director, Health Tech World
andrew@aspecthealthmedia.com

I

Latest health tech investment rounds

Atavistik Bio raises Series B funding

Value: $160 million
Stage: Series B funding round (announced March 2026)
Solution: Small-molecule drug discovery platform targeting previously “undruggable” proteins using allosteric inhibitors for rare blood disorders and cancer therapies.
Investors: RA Capital Management, Regeneron Ventures and other institutional investors.
Significance: Demonstrates continued venture capital interest in next-generation drug discovery platforms, particularly those addressing complex diseases using novel molecular targeting approaches.

Minnesota Medical Technologies secures Series A funding

Value: $20.6 million
Stage: Series A financing (announced March 2026)
Solution: Medical technology platform focused on advanced continence care devices designed to improve management of fecal incontinence and patient quality of life.
Investors: Co-led by HM Venture Partners and Southeast Minnesota Capital Partners.
Significance: Highlights growing investor interest in medical device innovation addressing chronic conditions with large but underserved patient populations.

Noxon raises seed funding for neuromuscular interface technology

Value: Not publicly disclosed (multi-million-euro seed round)
Stage: Seed funding round (announced March 2026)
Solution: Non-invasive muscle-computer interface technology designed to decode neuromuscular signals and restore motor control in conditions such as Parkinson’s disease or paralysis.
Investors: High-Tech Gründerfonds, Bayern Kapital, Auxxo and other institutional investors.
Significance: Reflects increasing investment in neurotechnology and human-machine interface platforms aimed at restoring mobility and improving neurological rehabilitation outcomes.

Big Health raises funding for digital therapeutics

Value: $23.7 million
Stage: Venture funding round (announced February 2026)
Solution: Digital therapeutics platform delivering clinically validated cognitive behavioural therapy apps for conditions including insomnia and anxiety.
Investors: Multiple venture investors supporting the expansion of app-based medical treatments.
Significance: Signals renewed investor confidence in digital therapeutics companies after several challenging years for the sector.

TruDoc Healthcare raises pre-Series B funding

Value: $15 million
Stage: Pre-Series B funding round (announced March 2026)
Solution: AI-enabled digital health platform providing virtual care services, telehealth consultations and population health monitoring tools.
Investors: Investment participation from the Al Nahyan family and other investors.
Significance: Illustrates the continued growth of AI-enabled telehealth platforms as healthcare systems increasingly adopt remote care models.

Eight Sleep secures funding to expand AI-driven health platform

Value: $50 million
Stage: Venture funding round (announced March 2026)
Solution: AI-powered sleep health platform combining biometric sensors, smart mattresses and software analytics to monitor and optimise sleep health.
Investors: Led by Tether Investments.
Significance: Highlights the convergence of consumer health technology, AI analytics and digital health platforms focused on preventative wellness and chronic disease management.

Cent secures funding for AI disease detection platform

Value: Not publicly disclosed
Stage: Venture funding round (announced March 2026)
Solution: AI-driven healthcare platform designed to support early disease detection and predictive diagnostics through advanced data analysis.
Investors: OneFlow Holdings and venture capital firm South Park Commons.
Significance: Reflects strong investor interest in AI-enabled healthcare diagnostics and preventative medicine technologies.

OpenEvidence raises major funding round for AI medical research platform

Value: $250 million
Stage: Venture funding round (announced January 2026)
Solution: AI-powered medical research assistant platform designed for clinicians, trained on peer-reviewed medical journals to support evidence-based clinical decision making and medical research workflows.
Investors: Thrive Capital, DST Global, Google Ventures, Nvidia, Mayo Clinic Ventures and other institutional investors.
Significance: Demonstrates the rapid growth of generative AI tools designed specifically for healthcare professionals, reflecting strong investor demand for clinical AI platforms capable of integrating scientific literature with real-time decision support.

Pontiro raises funding for AI health data anonymisation platform

Value: £357,500
Stage: Early-stage investment round (announced March 2026)
Solution: AI-driven platform designed to anonymise and de-identify medical images and clinical reports, enabling healthcare organisations to securely share patient data for research and AI development.
Investors: SFC Capital, British Business Bank and Plug and Play Ventures.
Significance: Addresses a major bottleneck in healthcare AI development — secure data access — by enabling privacy-compliant medical data sharing for research and clinical innovation.

Latest health tech deals

OURA → DoublePoint

Value: Not publicly disclosed
Stage: Acquisition (completed March 2026)
Solution: Gesture-recognition software technology enabling hands-free interaction with wearable devices — integrates with Oura’s health-tracking ring platform to support new ambient computing and AI-driven interaction capabilities.
Investors: Buyer — Oura; Sellers — Doublepoint founders and investors.
Significance: Expands the capabilities of wearable health technology beyond passive monitoring by enabling gesture-based interaction, supporting the next generation of AI-powered health and wellness ecosystems.

Azenta → UK Biocentre

Value: Not publicly disclosed
Stage: Acquisition (completed March 2026)
Solution: Biobanking, genomic sample management and high-throughput laboratory services — adds large-scale biological sample storage and research infrastructure to Azenta’s life sciences platform.
Investors: Buyer — Azenta (through Azenta UK Ltd); Sellers — UK Biocentre stakeholders.
Significance: Strengthens Azenta’s global biorepository network and supports growing demand for genomic and precision medicine research by expanding sample storage and laboratory capacity in Europe.

Guardant Health → MetaSight

Value: Up to $150 million
Stage: Acquisition (announced February 2026)
Solution: AI-driven cancer diagnostics technology designed to improve early detection and precision oncology through advanced molecular analysis and biomarker discovery.
Investors: Buyer — Guardant Health; Sellers — MetaSight founders and investors.
Significance: Reinforces the shift toward AI-enabled cancer screening and liquid biopsy diagnostics, expanding Guardant Health’s oncology testing capabilities and strengthening its precision medicine platform.

Esperion Therapeutics→ Corstasis Therapeutics

Value: Not publicly disclosed
Stage: Acquisition agreement announced March 2026
Solution: Cardiovascular therapeutic pipeline including bumetanide nasal spray (Enbumyst) designed to address fluid overload in heart failure patients.
Investors: Buyer — Esperion Therapeutics; Sellers — Corstasis Therapeutics stakeholders.
Significance: Expands Esperion’s cardiovascular treatment portfolio and demonstrates continued consolidation within biotech companies focused on cardiometabolic disease innovation.

GSK acquires → 35Pharma

Value: Up to $950 million including milestone payments
Stage: Acquisition agreement announced February 2026
Solution: Biologic drug candidate targeting pulmonary hypertension, strengthening GSK’s pipeline of treatments for rare cardiovascular diseases.
Investors: Buyer — GSK; Sellers — 35Pharma shareholders.
Significance: Illustrates continued investment by major pharmaceutical companies in rare disease therapeutics and reinforces the strategic importance of specialised biotech innovation pipelines.

Illumina→ SomaLogic assets

Value: $350 million upfront plus milestone payments
Stage: Acquisition completed January 2026
Solution: Proteomics and multi-omics research technologies enabling large-scale protein analysis alongside genomic data to advance precision medicine research.
Investors: Buyer — Illumina; Seller — Standard BioTools (SomaLogic assets).
Significance: Expands Illumina’s capabilities beyond DNA sequencing into multi-omics platforms, reflecting the growing convergence of genomics, proteomics and data analytics in biomedical research.

W. L. Gore→ Conformal Medical

Value: Up to approx. $50M (cash, stock, earnouts)
Stage: Advance agreement (target closing Q1 2026)
Solution: Healthcare Triangle signed a pact to acquire AI customer engagement assets from Spain-based Teyame AI, extending its digital health/AI portfolio with advanced CX/AI technologies.
Investors: Buyer — Healthcare Triangle; Seller — Teyame AI / asset holders
Significance: Signals targeted consolidation of AI customer-engagement tech into health IT portfolios, strengthening provider-facing engagement tools and analytics for care management and patient communication.

"We want everyone to have the chance to help shape the safest and most advanced AI-enabled healthcare system in the world at this truly pivotal moment."

Lawrence Tallon, chief executive of the MHRA, the UK medical body which is seeking input into a new commission on AI in health

(source: MHRA)

a computer circuit board with a brain on it

Latest collaborations in the sector

Tempus × Merck
Tempus has announced a strategic collaboration agreement with Merck to support AI-driven precision medicine, with the partnership focused on using Tempus’s data, machine learning and analytics capabilities to help identify novel biomarkers, understand cancer resistance mechanisms and inform combination strategies for Merck’s early oncology pipeline. The collaboration is designed to apply health-tech infrastructure directly to drug development, using multimodal data and AI to improve how therapies are matched, developed and refined. Significance: Highlights how health-tech platforms are becoming central partners in biopharma R&D, extending AI’s role from clinical workflow support into biomarker discovery and precision oncology strategy. 

Withings Health Solutions × 9amHealth
Withings Health Solutions has partnered with 9amHealth to strengthen employer-sponsored obesity care by combining connected body-composition monitoring with 9amHealth’s virtual cardiometabolic care model. The collaboration brings Withings’ remote patient monitoring devices and patient-generated data into a care pathway aimed at supporting obesity management and related metabolic conditions, giving care teams richer visibility between visits. Significance: Reinforces the growing link between connected devices and virtual specialty care, showing how health tech partnerships are being used to make chronic disease management more continuous, measurable and employer-friendly. 

Ubie × Mayo Clinic
Ubie has announced a collaboration with Mayo Clinic to build what the companies describe as a unified, AI-powered chat and voice platform for the digital front door. The partnership is intended to streamline healthcare access through natural-language interactions that help patients get answers, navigate triage and move more smoothly into scheduling and next-step care. Significance: Shows how provider organisations are increasingly using AI partnerships to modernise access and patient navigation, with the digital front door becoming a key battleground in health-tech innovation. 

Sibel Health × LookDeep Health
Sibel Health and LookDeep Health have entered a strategic partnership to combine Sibel’s FDA-cleared ANNE One wearable monitoring platform with LookDeep’s bedside clinical AI assistant, aimee. The collaboration is aimed at translating continuous vital-sign data into more actionable bedside insights across the hospital journey, from emergency care to inpatient recovery and into hospital-at-home or post-discharge settings. Significance: Strengthens the convergence of wearable monitoring and real-time clinical AI, pointing to a future in which continuous patient data is paired with decision support rather than simply collected and stored. 

Speechmatics × Edvak EHR
Speechmatics has partnered with Edvak EHR to embed enterprise-grade speech recognition into Edvak’s AI-native electronic health record platform. The collaboration is designed to convert live clinical conversations into structured, audit-ready documentation with clinician oversight, while also supporting downstream tasks such as referrals, coding and care coordination directly inside the EHR. Significance: Underlines the rapid push to turn voice AI into an operational layer inside clinical systems, with documentation automation increasingly tied to workflow execution rather than transcription alone. 

athenahealth × b.well
athenahealth and b.well have announced a collaboration to introduce patient-controlled digital health data sharing at the point of care. The partnership is intended to let patients more easily retrieve and share relevant health information during care encounters, helping to reduce friction for providers while giving individuals greater control over how their data moves across the system. Significance: Signals growing momentum behind patient-mediated interoperability, with health-tech firms trying to make data portability more practical in real clinical settings rather than a compliance exercise on paper. 

WHOOP × Unilabs
WHOOP has launched Advanced Labs in the UAE through a diagnostic partnership with Unilabs, combining laboratory testing with WHOOP’s wearable-driven wellness and recovery insights. The collaboration is intended to give members a more comprehensive view of health by linking biomarker testing with behavioural and physiological data captured through the wearable platform. Significance: Illustrates how consumer and clinical health tech are increasingly converging, with partnerships blending diagnostics and wearables to create more holistic monitoring models. 

CLEAR × Mount Sinai
CLEAR has announced a collaboration with the Mount Sinai Health System aimed at bringing more seamless and secure healthcare experiences to patients in New York. The partnership focuses on using CLEAR’s identity technology to simplify aspects of the patient journey while improving trust and reducing administrative friction in access and engagement. Significance: Shows that digital identity and verification are becoming a more visible part of health-tech collaboration, especially as providers look to modernise patient access without sacrificing security

a group of people standing next to each other

Latest funding wins and opportunities

ARPA-H backs seven teams through healthy-aging technology programme
ARPA-H announced on 24 February 2026 that it had selected seven research teams for its PROSPR programme, which is focused on developing tools, biomarkers and interventions aimed at detecting the earliest changes associated with ageing and extending healthspan. While the programme sits at the research end of the market, it is highly relevant to health tech because it combines diagnostics, measurement tools and novel trial design in an effort to shift care upstream. 

Axmed wins $6 million Gates Foundation grant
Health-tech company Axmed said on 17 February 2026 that it had secured $6 million in non-dilutive grant fundingfrom the Gates Foundation. The company said the money will support expansion of its B2B procurement and integrated logistics platform to improve access to affordable, quality-assured medicines in low- and middle-income countries. In practical terms, the award is a vote of confidence in digital infrastructure aimed at making healthcare supply chains more efficient and resilient. 

SEISMIC consortium secures €23.5 million IHI grant
A consortium led by major medtech and research partners, including Philips, announced on 11 February 2026 that it had secured a €23.5 million Innovative Health Initiative grant for the SEISMIC project. The programme is focused on next-generation minimally invasive brain treatments, bringing together imaging, intervention and data capabilities in an effort to improve precision and outcomes. The grant stands out as a sizeable public-private award for advanced therapeutic and medtech innovation. 

PreciseOnco awarded €14.9 million for precision cancer technology work
Another IHI-backed consortium, PreciseOnco, announced on 3 February 2026 that it had been awarded €14.9 million to support breakthroughs in precision cancer treatment. The project is centred on improving how cancer therapies are matched and evaluated, with clear relevance for diagnostics, imaging, digital analysis and personalised care tools. It is a strong example of grant funding flowing into collaborative health-tech infrastructure rather than a single product alone. 

Sibel Health adds new FDA grant support for digital endpoints
Sibel Health said in a February 2026 announcement that it had recently won a new $500,000 FDA grant to fully qualify its scratch sensor as a digital endpoint for atopic dermatitis. The company said the latest award takes its direct FDA funding for digital endpoint development to more than $1 million in total. The development is notable because it shows regulators and public funders continuing to support wearable sensors not just as devices, but as validated measurement tools for clinical research and drug development. 

NIHR opens i4i THRIVE call for early-stage innovations tackling health inequalities
The UK’s NIHR is set to open its i4i THRIVE - March 2026 opportunity on 12 March 2026, offering £150,000 plus training support for early-stage innovations designed to tackle health inequalities. NIHR says the programme is intended for university researchers and NHS clinicians developing novel technologies who would benefit from entrepreneurial mentoring and commercialisation support. For health-tech founders and academic innovators, it is one of the clearest near-term UK opportunities in the period. 

ARPA-H launches CIRCLE funding opportunity for ICU monitoring and AI
On 17 February 2026, ARPA-H launched its CIRCLE programme, aimed at improving how clinicians monitor and manage immune responses during critical illness. The agency says the programme will combine AI, advanced diagnostics and real-time immune monitoring, with solution summaries due on 30 March 2026 and full proposals due on 28 May 2026. The opportunity is particularly relevant to health tech because it links sensing, analytics and clinical decision support in a high-acuity care setting. 

INOVAIT opens Winter 2026 Pilot Fund for image-guided therapy and AI projects
Canada’s INOVAIT announced on 26 January 2026 that it had opened applications for its Winter 2026 Pilot Fund, a non-dilutive programme supporting R&D projects in image-guided therapy and artificial intelligence. The fund is aimed at helping teams advance translational projects in one of the most active intersections of medtech and digital health. For startups and academic-industry collaborations working in imaging, intervention and AI-enabled workflows, it is a timely new funding route. 

EIC opens 2026 funding opportunities worth more than €1.4 billion
The European Innovation Council has opened its 2026 work programme, which the Commission says makes available more than €1.4 billion in funding opportunities. For health-tech companies, the most relevant route is the EIC Accelerator, which offers grants below €2.5 million and equity investments of up to €10 million for high-risk innovations, including startups and SMEs developing disruptive products and services. While not health-only, it remains one of Europe’s biggest live funding channels for ambitious medtech and digital health ventures. 

NIHR opens quantum technology competition for healthcare applications
NIHR’s i4i programme opened its FAST - Quantum Technology competition on 10 February 2026, seeking proposals for quantum technologies in healthcare applications spanning prevention, diagnosis and precision medicine. The call has since closed, but it was a notable example in the last six weeks of a funder explicitly targeting frontier technologies for clinical use cases. It also suggests growing appetite among public funders for health-tech projects that go beyond conventional software and devices

time lapse photography of people passing on bridge

Recent healthcare data and cybersecurity breaches


University of Hawaiʻi Cancer Center discloses major research-data cyberattack
The University of Hawaiʻi said on 27 February 2026 that a cyberattack on the UH Cancer Center’s Epidemiology Division may have exposed records containing Social Security numbers, driver’s licence-linked identifiers and some health-related research data. The university said the incident potentially affects 87,493 Multiethnic Cohort study participants plus roughly 1.15 million additional individuals whose historical driver’s licence or voter-registration records were used in research recruitment, although it added that clinical trials operations, patient care and student records were not affected. The breach stands out because it hit a research environment rather than frontline care systems, exposing the cybersecurity risks around long-retained population-health datasets. 

University of Mississippi Medical Center hit by ransomware attack
The University of Mississippi Medical Center confirmed on 20 February 2026 that it had suffered a ransomware attackaffecting core systems, including its electronic health record and phone systems. In a message from the vice chancellor, UMMC said the incident forced it to use downtime procedures, cancel statewide clinic operations and elective procedures for two days, and prioritise urgent and time-sensitive care while recovery work continued. The case is notable less for exposed data totals than for the immediate operational disruption to a major academic medical centre. 

Lakelands Public Health reports cyber incident affecting internal systems
Ontario’s Lakelands Public Health said on 3 February 2026 that it was responding to a cybersecurity incident discovered on 29 January 2026 that affected some internal systems and caused temporary service disruptions. The agency said systems housing infectious-disease and clinical appointment data, including immunisation and sexual-health appointments, had not been impacted based on what it knew at that stage, and that affected individuals would be contacted if the investigation later found that personal or personal health information had been compromised. The incident is a reminder that even when the most sensitive clinical systems are spared, cyberattacks can still disrupt public-health operations and communications. 

TriZetto provider-portal breach ripples across healthcare organisations
A breach at TriZetto Provider Solutions, a billing and eligibility-verification vendor used by healthcare providers, continued to surface across the sector in late January and February 2026. Deschutes County Health Services said on 29 January 2026 that the incident occurred in TriZetto’s own environment, may have exposed protected health information for more than 700,000 people, and led local agencies to notify affected patients directly; MercyOne similarly posted a notice on 9 February 2026 saying the compromised data may have included names, addresses, dates of birth, Social Security numbers, health-insurance identifiers and other demographic or health-insurance information. The episode is significant because it shows how a single vendor breach can cascade across multiple care organisations even when their own systems were not directly compromised. 

Variety Care warns patients after third-party breach involving eligibility data
Oklahoma-based Variety Care posted a breach notice stating that affected individuals would receive physical letters in January 2026 after learning that TriZetto Provider Solutions had suffered suspicious activity in a web portal used by provider customers. Variety Care said the unauthorised access dated back to November 2024 and may have involved names, addresses, dates of birth, Social Security numbers, health-insurance member numbers, insurer names and other demographic and health-insurance information, though it said no payment-card or bank-account data was involved. The incident highlights how downstream contractor breaches can expose protected health information well after the initial compromise began. 

Emanuel Medical Center notifies patients after unauthorised access to clinical files
Emanuel Medical Center issued a public notice on 17 February 2026 saying it was informing individuals about a cybersecurity incident involving unauthorised activity on its systems. The hospital said suspicious activity was detected on 22 May 2025, that an unauthorised third party is believed to have accessed part of its systems between 21 and 24 May 2025, and that affected files contained a wide range of information including names, dates of birth, contact details, government ID numbers, insurance information, diagnoses, treatment details, prescriptions, medical histories and lab reports. This was a more traditional provider breach, with the likely exposure of both personal and detailed clinical information. 

 

Health tech leaders on what’s really reducing clinical burden

The promise of health technology has long been efficiency. The reality, too often, has been friction. 

With that in mind, we asked Health Tech World members: 

What's one way health tech is actually reducing clinician burden versus just adding another system to log into?

Here’s what they told us.

Dr Paul Deffley, chief medical officer at Alcidion

The key is solving the data problem first. Most health tech has added to the burden by layering yet another system on top of fragmented, poorly integrated infrastructure - scattering patient information and forcing decisions with incomplete data.

Modern platforms like Miya Precision take a different approach: liberating data from application to build a shared patient record, so clinicians get a complete clinical picture without toggling between systems. 

That foundation is also what makes AI actually useful - surfacing the right information at the point of care, automating routine interactions and making it easy to see what needs attention. Less time lost to systems, and more time with patients.

Bas Jansen, COO at G2 Speech

Health tech reduces clinician burden when it works in the background and fits naturally into existing clinical systems, rather than demanding new workflows. 

Ambient AI that captures consultations and automatically produces accurate documentation removes hours of admin without disrupting how clinicians work. 

While clinicians will always need to log into core systems, the difference is technology that integrates seamlessly, reduces duplication, and runs quietly alongside care delivery. 

When designed well, health tech doesn’t ask clinicians to adapt to it, it adapts to them.

Derrick Measham, director of innovation at X-on Health

One meaningful way health tech reduces clinician burden is through genuine workflow integration. 

The issue in primary care is rarely a lack of tools, but a lack of connected ones. 

When patient intent is captured once and flows seamlessly from first contact, whether that’s by phone, online or with the GP receptionist, into triage and directly into the clinical record, duplication disappears. 

There is no rekeying, no chasing missing context, and no additional dashboards to manage. That reduces cognitive load, strengthens governance, and removes hidden admin work. 

If technology simply shifts tasks between systems, it has not reduced the burden at all.

NIHR HRC in Accelerated Surgical Care

The NIHR HRC in Accelerated Surgical Care has recently completed a study assessing the usefulness and cost-effectiveness of wearable sensors for knee replacement surgery.  

This would improve the quality of patient rehabilitation which is currently being affected by not having enough staff to monitor patients, provide feedback and adapt their exercises.   

Clinicians need health tech to reduce admin and capacity burden, whilst improving patient recovery and it is important that its use fits within standard care pathways.

Peter Corpe, Industry Lead Public Sector at Appian

A recent study revealed that the NHS is burdened with 7.5 million hours of extra work every week through process inefficiencies. With legacy technology remaining a significant obstacle to NHS efficiency. 

Today; clinicians, administrators & patients serve as the “automation widget” who move critical health processes through disconnected applications. 

This hinders productivity, obscures quality and is a primary cause of unreliability.

One clear way health tech can reduce this burden is by taking a “process first” approach to automation and integration, rather than a standalone, “application first” philosophy.  

Every NHS organisation is built on processes and when those workflows improve, so do the services delivered. 

Platforms with process automation and workflow orchestration help unify disparate systems, cut repetitive manual tasks and streamline administrative workflows. 

This offers a chance to work more efficiently to reduce workload pressures and create value with AI. 

Allowing clinicians more time for strategic activities that directly improve patient outcomes.

Dr Harry Thirkettle, director of health and innovation at Aire Logic  

For health tech to genuinely reduce clinician burden, it needs to remove steps from the pathway, not add yet another portal to log into. 

With elective lists still stubbornly long, the pre-op pathway is one of the most painful pinch points. The burden there isn't just volume, it's repetition. 

Long waits mean assessments get done twice, risk scores get recalculated from scratch, and clinical teams spend time chasing information that already exists somewhere in the system. That's time and energy that should be going to patients. 

We recently worked with an NHS trust to tackle this. 

Using data that's already sitting there such as demographics, procedure type, admission method and medications, we built an AI model that automates key parts of risk stratification, including predicting ASA category. 

There wasn’t new data collection or extra documentation burden. We just made the information that was already there work harder. 

That's the model that actually makes a difference. 

Technology that quietly does the heavy lifting in the background, surfacing the right information at the right moment, within the workflows clinicians are already using. 

When it works well, clinicians shouldn't really notice it's there. They just find they have more time for patients.

Dr Rachael Grimaldi, co-founder and chief medical officer, CardMedic

The health tech solutions that are genuinely reducing clinician burden are the ones that fit into existing workflows rather than demanding clinicians adapt to them. 

At CardMedic, we see this every day – when a nurse can instantly access a communication tool in the right language or format at the point of care, without logging into a separate system or hunting through a portal, that’s time saved and cognitive load reduced. 

The problem with so much health tech is that it’s designed around the technology, not the clinician or the patient. 

Real reduction in burden means fewer steps, not more – and it means solutions that work in the messy, pressured reality of a ward or an emergency department, not just in a product demo. 

Until we hold ourselves to that standard, we risk adding noise rather than removing it.

Nadine Carey-Whitehead, commercial director at Insource

Clinician burden is reduced when technology removes work rather than introducing another system to navigate. 

At Insource, our solutions focus on unifying data from multiple systems into a single, trusted view so clinicians aren’t wasting time searching for information, duplicating entries, or relying on manual spreadsheets. 

By automating reporting, streamlining workflows, and delivering real-time, actionable insights directly where clinicians work, we cut cognitive load and eliminate unnecessary administrative effort. 

The result is technology that genuinely supports frontline teams by reducing friction, improving flow, and giving clinicians more time to focus on what matters most: patient care.

NEWS

Could sleep app data help identify respiratory disease trends in England?

UK Health Security Agency and Sleep Cycle launch a research study focusing on how coughing and sleep-related signals can support earlier detection of respiratory trends in the UK

The UK Health Security Agency and Sleep Cycle have announced the beginning of a 12-week research collaboration to understand if privacy-preserved data collected through a sleep app can support traditional respiratory disease surveillance systems and early detection of respiratory virus patterns.

The study will analyse trends derived from anonymised and privacy-preserved data collected from the Sleep Cycle app between January 2023 and January 2026 – and Sleep Cycle’s Cough Radar, a public visualisation tool that shows the data aggregated trends in nightly coughing intensity across different regions in England. The study then aims to explore if these signals can provide earlier visibility into respiratory disease trends, including viruses such as influenza, RSV, and Covid-19.

By analysing sleep-based signals such as nighttime cough patterns, the study will investigate how this data corresponds to the UK’s existing hospital admission data and surveillance indicators, and whether it provides an earlier signal of rising infection rates.

This marks the first time that UKHSA will systematically assess sleep app data to better understand its potential as a tool for national epidemiological monitoring. It is also a significant step forward in Sleep Cycle’s evolution from a consumer sleep app to a contributor in population-level health research.

Professor Steven Riley, Chief Data Officer at UKHSA, said: “As an agency we are constantly exploring how we can use new technology, such as AI, to complement our existing surveillance systems, and this innovative partnership represents a potential important step toward integrating novel data streams into our national health intelligence.

“If successful, these insights could help us strengthen early warning systems for respiratory infections in the UK.”

Erik Jivmark, CEO of Sleep Cycle, said: “Sleep is one of the most consistent, passive windows into human health. With more than 3 billion nights across 180 countries in our library, we are excited to work with UKHSA to determine if sleep can reveal meaningful population-level signals that offer earlier visibility into respiratory trends.

“Our partnership with UKHSA reflects the strength of the nocturnal-breathing data we’ve gathered, and our commitment to helping public health agencies continue to build their proactive insight capability.”

Traditional disease surveillance relies on data gathered from laboratories, hospitals, and community reporting systems. UKHSA also monitors a wide range of domestic and international indicators that track early signs of potential respiratory trends across the UK.

Sleep data, however, remains largely unexplored as a population-level signal.

No UKHSA data will be shared with Sleep Cycle as part of this study. Analysis will be conducted on UKHSA’s secure systems by a dedicated UKHSA research team, supported by data scientists and epidemiologists from both organisations.

Sleep Cycle contributes only anonymised, privacy-preserved and aggregated insights from its own technology and user-consented data library. UKHSA will compare those trends against signals from its existing surveillance ecosystem.

Sleep Cycle’s data science and respiratory-signal research, including its proprietary audio-based cough detection technology, have demonstrated that nighttime cough behavior can correlate with real-world viral activity. This collaboration provides an opportunity to evaluate those findings within a national surveillance framework.

The collaboration supports both parties’ commitment to advancing scientific understanding and responsible use of digital health data for public benefit.

person holding yellow and white plastic toy

Latest additions to the health tech marketplace

Epic × Microsoft

Epic and Microsoft rolled out Copilot-enabled generative AI features across Epic’s EHR ecosystem, embedding Microsoft Azure OpenAI–powered tools directly into clinical workflows. The launch enables clinicians to auto-draft visit summaries, respond to patient messages, and generate ambient documentation from conversations, with outputs routed through Epic’s existing clinical safety and governance layers. Health systems can activate features selectively, with auditability and human review built in. Strategically, the release marks one of the first large-scale, production deployments of generative AI inside a dominant EHR, shifting AI from experimental add-ons to day-to-day operational tooling. For providers, the promise is reduced documentation burden and faster patient communication; for Epic, it reinforces platform stickiness as competitors race to integrate similar copilots. Roll-out is proceeding system-by-system rather than universally enabled at launch.

Dexcom × Apple Health

Dexcom introduced expanded Apple Health integration that allows real-time continuous glucose monitoring (CGM) data to flow more deeply into Apple’s health ecosystem, including trend visualisation alongside activity, sleep and nutrition metrics. The update improves background syncing and gives users richer longitudinal views without opening Dexcom’s standalone app. For people managing diabetes or metabolic health, the launch tightens the link between medical-grade sensors and consumer health platforms. Strategically, it reinforces the convergence of regulated medical devices with consumer operating systems, positioning CGMs as core inputs for broader preventive and lifestyle health experiences rather than condition-specific tools.

NHS England × Accurx

Accurx launched enhanced patient-initiated messaging and triage features across its NHS-embedded communications platform, expanding beyond one-way SMS into structured digital conversations that integrate with GP and community workflows. Patients can submit requests, images and responses that feed directly into clinical systems, while practices gain configurable routing and prioritisation tools. The update supports NHS policy goals around access, demand management and digital front doors, while keeping data within NHS-approved infrastructure. Strategically, the release moves Accurx further from messaging utility toward a lightweight care-coordination layer across primary and community care.

Babylon Health × New Clinical Triage AI Model (UK/US)

Babylon Health announced the go-live of an upgraded AI clinical triage engine that underpins its on-demand symptom checker and virtual care routing workflows. The new model incorporates multimodal inputs (text, symptom timelines, optional wearable metrics) and leverages federated health data to improve differential generation and urgency stratification — with versioning aligned to national guidelines in the UK and U.S. markets. The feature now powers booked triage sessions, clinician handoffs and care pathway suggestions, and is integrated into the Babylon app and provider dashboards without separate download. For patients, this rollout promises more precise care recommendations and streamlined navigation; for Babylon, it solidifies AI-assisted triage as a core differentiator in virtual care.

Teladoc Health × Enhanced Mental Health Platform (Global)

Teladoc Health went live with a major upgrade to its mental health platform, adding adaptive care journeys, real-time mood and behaviour tracking, and contextual support nudges based on session progress and wearable-linked data. The update — delivered within the main Teladoc app — includes new clinician-facing dashboards that summarise risk signals and progress metrics, as well as expanded content libraries for CBT, DBT and mindfulness support tailored to anxiety, depression and stress disorders. The rollout spans U.S. and international markets and is part of a broader “Connected Mental Health” strategy that ties longitudinal data to personalised care plans.

Epic × Healthy Planet Analytics Enhancements

Epic launched a new version of its Healthy Planet population analytics module, introducing predictive risk scoring and care gap prioritisation tools that harness machine learning models across EHR, claims and social determinants data. The enhancements deliver care-gap dashboards for payors and providers, automated cohort identification for quality programs (HEDIS and national screening benchmarks), and real-time performance monitors tied to incentive metrics. Rolled out across Epic’s hosted cloud environments, the update aims to help health systems improve preventive outreach, manage high-risk cohorts and reduce avoidable admissions.

MyFitnessPal × Nutrition Insight Engine Upgrade

MyFitnessPal issued a major content & algorithm upgrade to its nutrition tracking engine, powered by an expanded food database and AI-augmented portion estimation from images. The new version automatically classifies meals with improved macro/micronutrient accuracy and ties recommendations to user-specific health goals (e.g., metabolic health, blood glucose stability). While not a clinical device, this rollout strengthens the wellness side of health tech by giving consumers deeper actionable insight tied to personalized objectives and trends.

Recent changes affecting health tech and medtech innovations

FDA’s new device quality system regime takes effect
The FDA’s revised Quality Management System Regulation (QMSR) became effective on 2 February 2026, replacing the old inspection approach and aligning US device quality requirements more closely with ISO 13485:2016. The agency said it has stopped using the previous QSIT inspection method and moved to an updated inspection programme. For health-tech companies, especially software-enabled device and digital health manufacturers operating across markets, the change matters because it brings US compliance expectations closer to the global quality-management framework already used elsewhere. 

FDA opens TEMPO pilot for digital health devices
The FDA has begun accepting statements of interest for its TEMPO pilot, with the programme formally open from 2 January 2026 and follow-up requests to selected applicants beginning around 2 March 2026. The pilot is designed for digital health device manufacturers and is notable because FDA says participants may seek a statement that the agency does not intend to enforce certain legal requirements, including premarket authorisation and IDE requirements, in specific circumstances. In effect, it is a closely watched test of a more flexible regulatory pathway for selected digital health technologies tied to patient outcomes. 

FDA seeks feedback on real-world evaluation of AI medical devices
The FDA has also launched a request for public comment on how to measure and evaluate the real-world performance of AI-enabled medical devices, including approaches to monitoring performance drift and changes in inputs and outputs. The agency says the document is not draft or final guidance and is not intended to implement policy changes, but it clearly signals where regulatory thinking is heading as AI tools move from static submissions to continuous real-world use. For health tech, it is an important standards-style development because it frames the evidence and monitoring questions likely to shape future AI oversight. 

MHRA launches consultation on indefinite CE-mark recognition in Great Britain
The MHRA opened a consultation on 16 February 2026 on proposals to recognise CE-marked medical devices in Great Britain on a longer-term basis. The consultation covers extending transitional arrangements for older directive-compliant devices, indefinitely recognising devices compliant with the EU MDR and EU IVDR, and creating an international reliance route where devices are classified higher in Great Britain than in the EU. For health-tech companies, this is a major market-access development because it could materially affect how device and software manufacturers sequence UK and EU regulatory strategy. 

MHRA starts fee-waiver pilot for innovative device clinical investigations
In a separate UK move, the MHRA launched a pilot running from 5 January 2026 to 31 March 2026 that waives clinical investigation application fees for up to 10 eligible Class I, IIa or IIb innovative device studies from UK small and micro businesses. The agency said successful applicants will pay no clinical investigation application fee during the pilot. While modest in scale, the initiative is a practical regulatory development for early-stage health-tech and medtech firms because it lowers one barrier to generating the clinical evidence needed for market progress. 

TEFCA updates take effect for exchange purposes and FHIR workflows
The Sequoia Project’s TEFCA Recognized Coordinating Entity has put through several interoperability governance updates, including new versions of the Exchange PurposesTreatment, and Health Care Operations SOPs effective 15 February 2026, plus an updated Facilitated FHIR implementation SOP effective 8 March 2026. These are not laws, but they are highly consequential operating rules for participants in the US national health information exchange framework. For health-tech vendors working in interoperability, API connectivity and health data exchange, they amount to a meaningful standards development in how nationwide exchange is expected to function. 

US health IT standards shift fully away from older USCDI and API baselines
A standards transition that became live at the start of 2026 is now visible across ASTP/ONC certification materials: USCDI v1 and several older interoperability standards expired for adoption on 1 January 2026, while newer baselines such as USCDI v3, updated US Core FHIR, and newer SMART App Launch requirements became the required path by the end of 2025. The practical significance for certified health IT developers is that legacy standards have now dropped out of the current compliance baseline, raising the floor for interoperability, APIs and data-element support. 

The latest senior health tech hires

ThoroughCare appoints new CEO and chief growth officer
Care management and value-based care technology company ThoroughCare announced on 23 February 2026 that it had appointed Steve McGraw as chief executive officer and Renee DeSilva as chief growth officer. The company said the leadership changes are intended to support its next phase of expansion in care management and population health. The appointments suggest ThoroughCare is sharpening both operational leadership and go-to-market execution as demand grows for tech-enabled value-based care tools. 

CareDx expands Keith Kennedy’s remit to COO and CFO
CareDx announced on 24 February 2026 that Keith Kennedy would assume the responsibilities of chief financial officer while continuing in his existing role as chief operating officer, effective 26 February 2026. The transplant-focused precision medicine company said Kennedy will now oversee its finance organisation as well as operations. The move points to a tighter, more integrated leadership structure as CareDx continues to scale its diagnostics and data-driven transplant platform. 

Coloplast names Gavin Wood as new CEO
Coloplast said on 4 March 2026 that it had appointed Gavin Wood as its new president and chief executive officer, effective 1 May 2026. The medtech group, which is active in areas including continence care, ostomy and women’s health-related pelvic care, said Wood will succeed interim CEO Lars Rasmussen. The appointment is a significant leadership change at one of Europe’s best-known health technology companies, with implications across multiple device categories. 

VentureMed Group appoints Bruce Fiedler as CFO
VentureMed Group announced on 11 February 2026 that it had named Bruce Fiedler as chief financial officer. The vascular intervention company said Fiedler brings experience from high-growth healthcare and technology organisations, as it continues to develop and commercialise its minimally invasive device platform. The appointment signals a stronger finance focus as medtech firms look to balance innovation, commercial growth and capital discipline. 

Integra LifeSciences creates CTO role in leadership reshuffle
Integra LifeSciences announced on 17 February 2026 a set of executive leadership changes, including the appointment of Teshtar Elavia to the newly created role of chief technology officer. The company also named Michael Hutchinson as chief legal officer and Kerri DiPietro as chief quality officer. For a major medtech group, the creation of a CTO post is especially notable, underlining how product, platform and technology strategy are becoming more central at executive level. 

AdhereTech appoints Jeremy Gilbert as CEO
Medication adherence technology company AdhereTech said on 27 January 2026 that it had appointed Jeremy Gilbertas chief executive officer. Gilbert previously served as the company’s chief product development officer, and the business said the move is intended to accelerate growth across clinical trials and commercial adherence programmes. The promotion reflects the continued push to scale connected-device and digital support models that help patients stay on therapy. 

SBC Medical appoints Sheng-FU Hsiao as CTO
SBC Medical announced on 2 March 2026 that it had appointed Sheng-FU Hsiao as chief technology officer, effective 1 March 2026. The company said the move aligns with its 2026 strategy and will support development of a more scalable AI-driven medical management infrastructure built on its large global clinic data base. The appointment highlights how healthcare service platforms are increasingly elevating data and AI leadership to the C-suite. 

Advantmed appoints Dr Matt Lambert as chief medical officer and head of product strategy
Advantmed said on 3 March 2026 that it had appointed Dr Matt Lambert as chief medical officer and head of product strategy. The company, which focuses on risk adjustment and quality solutions, said the hire is intended to strengthen product direction and clinical leadership. The dual role shows how health-tech companies are increasingly combining clinical credibility with product strategy in a single executive position.

Expert debate: AI and care inclusivity

We recently hosted an online debate on the role of AI in speeding and supporting inclusive healthcare.

Guests joining our host Alastair MacColl include:

Dr Anushka Patchava, chief clinical and innovation officer, Cignpost Group

Josh Miller, CEO, Gradient Health

Sunil Daga, clinical associate professor and honorary consultant renal transplant physician, University of Leeds

Afshin Attari, senior director public sector & unified platforms, Exponential-e

Watch the online debate now

Get in touch

Advertising
gary@aspectpublishing.co.uk
sales@aspectpublishing.co.uk

Editorial
gordon@aspectpublishing.co.uk
editor@aspectpublishing.co.uk

www.htworld.co.uk


Health Tech World is part of Aspect Health Media Ltd, a specialist healthcare publisher focused on contributing to better patient outcomes through news, insights and the sharing of ideas. Other Aspect publications include Femtech World, for all the innovators working to close the gender health gap, Agetech World, which covers the global longevity sector, and Neuro Rehab Times, dedicated to brain and spinal professionals globally.

www.aspecthealthmedia.com

Aspect Health Media Ltd (Company Registration No: 10109188), 3 Berrymoor Court, Northumberland Business Park, Cramlington, Northumberland, United Kingdom, NE23 7RZ.